Extract

This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with MTX in RA.

Inclusion criteria

• Rheumatoid Arthritis

Country

• Belgium
• Czech Republic
• Germany
• Hungary
• Japan
• Korea, Republic of
• Poland
• Russian Federation
• Slovakia
• Taiwan, Province of China
• United States

Links

• ictrp
• nct